Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21071439
Carriere A, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286, 567-77 21071439
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
phorbol_ester no change compared to control
EGF no change compared to control

T202-p - ERK1 (human)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol_ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

Y204-p - ERK1 (human)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol_ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

T185-p - ERK2 (human)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol_ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

Y187-p - ERK2 (human)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester augment treatment-induced increase
HRas (human) increase
insulin no change compared to control
phorbol_ester insulin increase
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control

S380-p - p90RSK (human)
Modsite: HQLFRGFsFVATGLM SwissProt Entrez-Gene
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): , p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase

S8-p - Raptor (human)
Modsite: MESEMLQsPLLGLGE SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S8‑p, Raptor (mouse): S8‑p, Raptor (rat): S8‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  raptor S8/696/863A mutant
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK1 (human)
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, activation of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase

S696-p - Raptor (human)
Modsite: EKNYALPsPATTEGG SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S696‑p, Raptor (mouse): S696‑p, Raptor (rat): S696‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), 293 (epithelial) [Raptor (human), transfection], HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  raptor S8/696/863A mutant
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK1 (human)
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, activation of upstream enzyme
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester no effect upon treatment-induced increase
siRNA phorbol_ester inhibit treatment-induced increase siRNA ERK1/2
EGF increase
siRNA EGF inhibit treatment-induced increase siRNA ERK1/2
insulin no change compared to control
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control
phorbol_ester insulin increase

T706-p - Raptor (human)
Modsite: TTEGGSLtPVRDSPC SwissProt Entrez-Gene
Orthologous residues
Raptor (human): T706‑p, Raptor (mouse): T706‑p, Raptor (rat): T706‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester no change compared to control
U0126 phorbol_ester no change compared to control

S719-p - Raptor (human)
Modsite: PCTPRLRsVSSYGNI SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S719‑p, Raptor (mouse): S719‑p, Raptor (rat): S719‑p

S721-p - Raptor (human)
Modsite: TPRLRSVsSYGNIRA SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S721‑p, Raptor (mouse): S721‑p, Raptor (rat): S721‑p

S722-p - Raptor (human)
Modsite: PRLRSVSsYGNIRAV SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S722‑p, Raptor (mouse): S722‑p, Raptor (rat): S722‑p

S859-p - Raptor (human)
Modsite: DTSSLTQsAPASPTN SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S859‑p, Raptor (mouse): S859‑p, Raptor (rat): S859‑p

S863-p - Raptor (human)
Modsite: LTQSAPAsPTNKGVH SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S863‑p, Raptor (mouse): S863‑p, Raptor (rat): S863‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), 293 (epithelial) [Raptor (human), transfection], HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  raptor S8/696/863A mutant
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK1 (human)
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, activation of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
PD184352 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester no effect upon treatment-induced increase
siRNA phorbol_ester inhibit treatment-induced increase siRNA ERK1/2
EGF increase
siRNA EGF inhibit treatment-induced increase siRNA ERK1/2
insulin no change compared to control
PD184352 insulin no change compared to control
rapamycin insulin no change compared to control
phorbol_ester insulin increase

S877-p - Raptor (human)
Modsite: HIHQAGGsPPASSTS SwissProt Entrez-Gene
Orthologous residues
Raptor (human): S877‑p, Raptor (mouse): S877‑p, Raptor (rat): S877‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester no change compared to control
U0126 phorbol_ester no change compared to control

S235-p - S6 (human)
Modsite: IAKRRRLsSLRASTS SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLSsLRASTSK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase

S240-p - S6 (human)
Modsite: RLSSLRAsTSKSESS SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
serum increase
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase small decrease
rapamycin phorbol_ester inhibit treatment-induced increase small decrease
insulin increase
PD184352 insulin no effect upon treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
phorbol_ester insulin augment treatment-induced increase

S244-p - S6 (human)
Modsite: LRASTSKsESSQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
serum increase
phorbol_ester increase
PD184352 phorbol_ester inhibit treatment-induced increase small decrease
rapamycin phorbol_ester inhibit treatment-induced increase small decrease
insulin increase
PD184352 insulin no effect upon treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
phorbol_ester insulin augment treatment-induced increase